3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
8
Neoplasms
6
Stomach Neoplasms
5
Prostatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Oropharyngeal Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Fatigue
4
Urinary Bladder Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Myasthenia Gravis
3
Mouth Neoplasms
3
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Weight Loss
2
Peritoneal Neoplasms
2
Pancreatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Squamous Cell
2
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphatic Abnormalities
×
30 days
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled